Group 1 - BiomX (PHGE) has entered into definitive agreements for a private investment in public equity financing, expecting gross proceeds of approximately $3 million before deducting fees and expenses [1] - H.C. Wainwright & Co. is acting as the exclusive placement agent for this private placement [1] - The company will issue Series Y Convertible Preferred Stock with a stated value of $1,000 per share, along with warrants valued up to $3.3 million, for a total purchase price of $3 million [1] Group 2 - The Series Y Convertible Preferred Stock will accrue dividends at a rate of 15% per annum, payable quarterly, and will mature one year from the closing date [1] - Each share of Series Y Convertible Preferred Stock is convertible into common stock, subject to stockholder approval as required under NYSE American rules [1] - The company will issue warrants to acquire up to 3,300,000 shares of common stock, with a five-year term and an initial exercise price of $2.00 [1] Group 3 - The private placement is expected to close on or about December 30, pending the satisfaction of customary closing conditions [1]

Core Viewpoint - BiomX Inc. (PHGE) has been upgraded to a Zacks Rank 2 (Buy), indicating an upward trend in earnings estimates which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value for a stock, prompting institutional investors to buy or sell, thus affecting stock prices [4]. Company Performance and Outlook - The upgrade for BiomX reflects an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [5]. - Over the past three months, the Zacks Consensus Estimate for BiomX has increased by 11.7%, indicating positive revisions in earnings estimates [8]. Zacks Rating System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with only the top 20% receiving a "Strong Buy" or "Buy" rating, highlighting superior earnings estimate revisions [9][10]. - Stocks rated Zacks Rank 1 have historically generated an average annual return of +25% since 1988, showcasing the effectiveness of the rating system [7].

Proceeds to Support the Company’s Assessment of Opportunities to Advance BX011 and Ongoing Evaluation of Strategic AlternativesNESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity (“Private Placement”) financin ...

NESS ZIONA, Israel, Dec. 29, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies targeting specific pathogenic bacteria, today announced that it has entered into definitive agreements in connection with a private investment in public equity ("Private Placement") financing for expected gross proceeds of approximately $3.0 million, before deducting placement agent fees and other offering expenses. H.C. Wain ...

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index dropping over 200 points, down 0.46% to 47,733.58. The NASDAQ fell 0.32% to 23,501.92, and the S&P 500 also decreased by 0.46% to 6,838.69 [1] - In the commodities market, oil prices fell by 1.6% to $59.14, gold decreased by 0.6% to $4,219.60, silver dropped 1.1% to $58.395, and copper fell 0.7% to $5.4225 [5] Sector Performance - Information technology shares increased by 0.6% on Monday, while communication services stocks saw a decline of 2.1% [1] European Market - European shares showed mixed results, with the eurozone's STOXX 600 falling 0.07%, Spain's IBEX 35 Index rising 0.14%, London's FTSE 100 down 0.23%, Germany's DAX 40 gaining 0.07%, and France's CAC 40 falling 0.08% [6] Asian Market - Asian markets closed mixed, with Japan's Nikkei rising 0.18%, Hong Kong's Hang Seng dipping 1.23%, China's Shanghai Composite increasing by 0.54%, and India's BSE Sensex declining by 0.71% [7] Company News - Structure Therapeutics Inc. saw its shares surge 100% to $68.95 following the announcement of positive topline data from its ACCESS clinical program for aleniglipron, aimed at treating obesity [9] - Wave Life Sciences Ltd. shares increased by 124% to $16.77 after reporting positive interim Phase 1 data for its obesity drug WVE-007 [9] - Fulcrum Therapeutics, Inc. shares rose 63% to $14.50 after initial results from its Phase 1b PIONEER trial of Pociredir in sickle cell disease showed promising outcomes [9] - SMX (Security Matters) Public Limited Company shares dropped 57% to $141.56 after a significant rise of 135% on the previous Friday [9] - BiomX Inc. shares fell 33% to $3.4398 after discontinuing its Phase 2b trial of BX004 in cystic fibrosis patients [9] - Meihua International Medical Technologies Co., Ltd. shares decreased by 38% to $8.66 following the announcement of its delisting from Nasdaq [9]

Market Overview - U.S. stocks experienced a decline, with the Dow Jones index falling over 200 points, down 0.46% to 47,733.58. The NASDAQ decreased by 0.32% to 23,501.92, and the S&P 500 also fell 0.46% to 6,838.69 [1] Sector Performance - Information technology shares increased by 0.6% on the same day, while communication services stocks dropped by 2.1% [1] Commodity Prices - Oil prices fell by 1.6% to $59.14, gold decreased by 0.6% to $4,219.60, silver dropped by 1.1% to $58.395, and copper fell by 0.7% to $5.4225 [5] European Market Performance - European shares showed mixed results, with the eurozone's STOXX 600 down 0.07%, Spain's IBEX 35 Index up 0.14%, London's FTSE 100 down 0.23%, Germany's DAX 40 up 0.07%, and France's CAC 40 down 0.08% [6] Asian Market Performance - Asian markets closed mixed, with Japan's Nikkei rising 0.18%, Hong Kong's Hang Seng down 1.23%, China's Shanghai Composite up 0.54%, and India's BSE Sensex declining 0.71% [7] Company News - Structure Therapeutics Inc. saw its shares surge 100% to $68.95 following positive topline data from its clinical program for obesity treatment [9] - Wave Life Sciences Ltd. shares increased by 124% to $16.77 after reporting positive interim Phase 1 data for its obesity drug [9] - Fulcrum Therapeutics, Inc. shares rose 63% to $14.50 after initial results from its Phase 1b trial showed promising outcomes in sickle cell disease [9] - SMX Public Limited Company shares dropped 57% to $141.56 after a significant rise the previous day [9] - BiomX Inc. shares fell 33% to $3.4398 after discontinuing its Phase 2b trial for cystic fibrosis [9] - Meihua International Medical Technologies Co., Ltd. shares decreased by 38% to $8.66 following the announcement of its delisting from Nasdaq [9]

Core Insights - BiomX has decided to discontinue the Phase 2b trial of BX004 for cystic fibrosis due to high rates of adverse events identified in a safety review by the Data Monitoring Committee [1][2] - The company is focusing on its phage program BX011 for Staphylococcus aureus infections related to diabetic foot infections while implementing cost-cutting measures, including workforce reduction [1][2][3] Company Overview - BiomX is a clinical-stage company developing natural and engineered phage therapies aimed at treating chronic diseases with significant unmet medical needs [4] - The company utilizes its BOLT platform to customize phage compositions targeting specific bacterial pathogens [4]

Core Viewpoint - BiomX Inc. is currently under FDA evaluation for its nebulizer device used in the Phase 2b trial of BX004 for cystic fibrosis, with a clinical hold in place due to data review concerns regarding the device [1][2][3]. Group 1: FDA Evaluation and Clinical Hold - The FDA has placed a clinical hold on the Phase 2b study while reviewing data submitted by BiomX regarding the third-party nebulizer used for BX004 delivery [2][4]. - No concerns were raised about the BX004 drug candidate itself in the clinical hold notification, and patient enrollment and dosing outside the U.S. continue as per protocol [3][4]. Group 2: Company Actions and Future Expectations - BiomX is collaborating with the nebulizer manufacturer to address the FDA's follow-up information requests, which are considered readily addressable [4]. - The company anticipates that U.S. enrollment will resume once the FDA's concerns are resolved, and topline results are now expected in the second quarter of 2026 following protocol updates [5][6]. Group 3: Financial Position and Stock Performance - As of September 30, 2025, BiomX reported a cash balance of $8.1 million, which is projected to fund operations into the first quarter of 2026 [7]. - BiomX shares experienced a decline of 7.18%, trading at $5.36, close to its 52-week low of $4.65 [7].

Core Viewpoint - BiomX Inc. is addressing FDA follow-up information requests to lift the clinical hold on its Phase 2b trial for BX004, a treatment targeting Pseudomonas aeruginosa in cystic fibrosis patients, with topline results now expected in Q2 2026 [1][4][5] Company Updates - The FDA is continuing its evaluation of the nebulizer device used for BX004 administration, and BiomX is collaborating with the third-party manufacturer to provide the necessary information [1][2] - An independent Data Monitoring Committee (DMC) has completed a safety review of the BX004 Phase 2b trial and recommended that the study continue with an adjusted dosing regimen [3][4] - The trial protocol will be updated accordingly, and pending financial resources, the company expects to enroll approximately 60 patients in the Phase 2b trial [5] Product Information - BX004 is a fixed multi-phage cocktail designed to target Pseudomonas aeruginosa, which significantly impacts morbidity and mortality in cystic fibrosis patients [5] - Positive results from earlier phases of the trial indicated safety, tolerability, and improvement in pulmonary function associated with reduced bacterial load [5] Future Expectations - The company remains optimistic about the path forward for BX004 and looks forward to reporting topline results in the second quarter of 2026 [4][5]

Core Insights - BiomX Inc. is addressing FDA follow-up information requests to lift the clinical hold on the nebulizer device used in the Phase 2b trial of BX004 for cystic fibrosis patients [1][2][4] - An independent Data Monitoring Committee (DMC) has reviewed the safety of the BX004 Phase 2b trial and recommended that the study continue with an adjusted dosing regimen, with topline results now expected in Q2 2026 [3][4] Company Updates - The company is collaborating with a third-party manufacturer to provide the FDA with the necessary information to resolve outstanding questions regarding the nebulizer device [2][4] - BiomX has previously reported positive results from Part 1 and Part 2 of the Phase 1b/2a trials, demonstrating safety, tolerability, and improvement in pulmonary function in a specific patient subgroup [5] Product Information - BX004 is a multi-phage cocktail targeting Pseudomonas aeruginosa, a significant cause of morbidity in cystic fibrosis patients [5] - The company plans to enroll approximately 60 patients in a randomized, double-blind, placebo-controlled Phase 2b trial, pending the resolution of the FDA clinical hold [5]